- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
These Two Words Could Change Obesity Treatment, says Harold Bays, MD
Long time cardiometabolic investigator Harold Bays, MD, talks about obesity, new drugs to treat the disease, and how the words "be inefficient" could change thinking about treatment.
Harold Bays, MD, is widely recognized for his research in cardiometabolic disease and, as he told Patient Care Online during a recent interview, he has been a principal investigator for a long time. "I was there when we developed all the diabetes drugs and antihypertension drugs and lipid drugs."
Bays now is very optimistic about the approval of new medications for the treatment of obesity and says primary care clinicians are going to be essential in getting them to appropriate patients. In this interview he also highlights a topic he discussed in a presentation at the Obesity Medicine Association's Virtual Spring Summit on April 23, 2021: how the 2 words "be inefficient" can change the approach to obesity treatment.
Harold Bays, MD, is medical director of the Louisville Metabolic and Atherosclerosis Research Center, Inc, Chief Science Officer at the Obesity Medicine Association, and widely known for his research in cardiometabolic disease.
